Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    Since there are multiple therapeutic options available for patients with metastatic castration-resistant prostate cancer (mCRPC), it’s important to balance efficacy, safety, and patient preferences when selecting and sequencing treatments. That’s why Dr. Charles Turck speaks with Drs. Hannah McManus and Andrew Armstrong about the complexities of treatment selection and sequencing in metastatic castration-resistant prostate cancer (mCRPC) care.

Recommended
Details
Presenters
Related
Comments
  • Overview

    Since there are multiple therapeutic options available for patients with metastatic castration-resistant prostate cancer (mCRPC), it’s important to balance efficacy, safety, and patient preferences when selecting and sequencing treatments. That’s why Dr. Charles Turck speaks with Drs. Hannah McManus and Andrew Armstrong about the complexities of treatment selection and sequencing in metastatic castration-resistant prostate cancer (mCRPC) care.

Schedule9 Dec 2024